Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.
The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.
San Diego, California Friday, January 10, 2025, 10:00 Hrs [IST] ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...
Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback